Vera Therapeutics, Inc. (VERA) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Brisbane, CA, アメリカ. 現CEOは Marshall W. Fordyce.
VERA を有する IPO日 2021-05-14, 152 名の正社員, に上場 NASDAQ Global Market, 時価総額 $3.17B.
Vera Therapeutics, Inc. is a clinical-stage biotechnology company developing treatments for serious immunological diseases in the United States. The company's lead candidate, atacicept, is a fusion protein administered via subcutaneous injection currently in Phase IIb trials for immunoglobulin A nephropathy. Vera is also advancing MAU868, a monoclonal antibody in Phase 2 development for treating BK viremia infections. Founded in 2016 and headquartered in Brisbane, California, the company was previously known as Trucode Gene Repair, Inc. before rebranding as Vera Therapeutics in April 2020.
